Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major rheumatoid arthritis markets reached a value of US$ 27.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 33.8 Billion by 2034, exhibiting a growth rate (CAGR) of 1.88% during 2024-2034.
The rheumatoid arthritis market has been comprehensively analyzed in IMARC's new report titled "Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Rheumatoid arthritis refers to a chronic autoimmune disorder that primarily affects the joints, leading to inflammation, pain, and stiffness. In this condition, the body's immune system mistakenly attacks the synovial membrane, which lines the joints, resulting in inflammation, thickening of the synovium, and damage to the surrounding cartilage and bone. The most common symptoms are joint pain, stiffness, and swelling, which can be present in multiple joints and may worsen in the morning or after periods of inactivity. As the disease progresses, joints may become deformed, limiting mobility. The ailment can also affect other body parts, such as the lungs, eyes, heart, etc. The diagnosis of rheumatoid arthritis typically involves a combination of physical examination, medical history, blood tests, and imaging procedures. The physical exam includes assessing joint mobility, checking for swelling or tenderness, and looking for other signs of inflammation. Several blood tests are performed to look for specific antibodies and inflammatory markers. Numerous imaging studies, such as X-rays and ultrasounds, are also used to assess joint damage and monitor disease progression.
The rising cases of immune system dysfunction, which leads to inflammation, pain, and damage to the joints, are primarily driving the rheumatoid arthritis market. In addition to this, the increasing prevalence of associated risk factors, such as genetic predisposition, excessive smoking, exposure to certain pollutants, infections, etc., is further bolstering the market growth. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen and naproxen, for reducing inflammation and swelling in the joints is also creating a positive outlook for the market. Additionally, the ongoing advancements in the field of biomarker research are leading to the development of more accurate and sensitive tests for the ailment, such as anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) tests. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the inflating demand for disease-modifying antirheumatic drugs (DMARDs), including methotrexate, sulfasalazine, leflunomide, etc., which aid in slowing down the progression of the ailment by suppressing the immune system's attack on the joints, is expected to drive the rheumatoid arthritis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the rheumatoid arthritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for rheumatoid arthritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the rheumatoid arthritis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the rheumatoid arthritis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the rheumatoid arthritis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current rheumatoid arthritis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the rheumatoid arthritis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the rheumatoid arthritis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the rheumatoid arthritis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of rheumatoid arthritis across the seven major markets?
What is the number of prevalent cases (2018-2034) of rheumatoid arthritis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of rheumatoid arthritis by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of rheumatoid arthritis by type across the seven major markets?
How many patients are diagnosed (2018-2034) with rheumatoid arthritis across the seven major markets?
What is the size of the rheumatoid arthritis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of rheumatoid arthritis?
What will be the growth rate of patients across the seven major markets?
Rheumatoid Arthritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for rheumatoid arthritis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the rheumatoid arthritis market?
What are the key regulatory events related to the rheumatoid arthritis market?
What is the structure of clinical trial landscape by status related to the rheumatoid arthritis market?
What is the structure of clinical trial landscape by phase related to the rheumatoid arthritis market?
What is the structure of clinical trial landscape by route of administration related to the rheumatoid arthritis market?
The rheumatoid arthritis market has been comprehensively analyzed in IMARC's new report titled "Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Rheumatoid arthritis refers to a chronic autoimmune disorder that primarily affects the joints, leading to inflammation, pain, and stiffness. In this condition, the body's immune system mistakenly attacks the synovial membrane, which lines the joints, resulting in inflammation, thickening of the synovium, and damage to the surrounding cartilage and bone. The most common symptoms are joint pain, stiffness, and swelling, which can be present in multiple joints and may worsen in the morning or after periods of inactivity. As the disease progresses, joints may become deformed, limiting mobility. The ailment can also affect other body parts, such as the lungs, eyes, heart, etc. The diagnosis of rheumatoid arthritis typically involves a combination of physical examination, medical history, blood tests, and imaging procedures. The physical exam includes assessing joint mobility, checking for swelling or tenderness, and looking for other signs of inflammation. Several blood tests are performed to look for specific antibodies and inflammatory markers. Numerous imaging studies, such as X-rays and ultrasounds, are also used to assess joint damage and monitor disease progression.
The rising cases of immune system dysfunction, which leads to inflammation, pain, and damage to the joints, are primarily driving the rheumatoid arthritis market. In addition to this, the increasing prevalence of associated risk factors, such as genetic predisposition, excessive smoking, exposure to certain pollutants, infections, etc., is further bolstering the market growth. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen and naproxen, for reducing inflammation and swelling in the joints is also creating a positive outlook for the market. Additionally, the ongoing advancements in the field of biomarker research are leading to the development of more accurate and sensitive tests for the ailment, such as anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) tests. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the inflating demand for disease-modifying antirheumatic drugs (DMARDs), including methotrexate, sulfasalazine, leflunomide, etc., which aid in slowing down the progression of the ailment by suppressing the immune system's attack on the joints, is expected to drive the rheumatoid arthritis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the rheumatoid arthritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for rheumatoid arthritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the rheumatoid arthritis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the rheumatoid arthritis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the rheumatoid arthritis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current rheumatoid arthritis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the rheumatoid arthritis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the rheumatoid arthritis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the rheumatoid arthritis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of rheumatoid arthritis across the seven major markets?
What is the number of prevalent cases (2018-2034) of rheumatoid arthritis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of rheumatoid arthritis by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of rheumatoid arthritis by type across the seven major markets?
How many patients are diagnosed (2018-2034) with rheumatoid arthritis across the seven major markets?
What is the size of the rheumatoid arthritis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of rheumatoid arthritis?
What will be the growth rate of patients across the seven major markets?
Rheumatoid Arthritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for rheumatoid arthritis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the rheumatoid arthritis market?
What are the key regulatory events related to the rheumatoid arthritis market?
What is the structure of clinical trial landscape by status related to the rheumatoid arthritis market?
What is the structure of clinical trial landscape by phase related to the rheumatoid arthritis market?
What is the structure of clinical trial landscape by route of administration related to the rheumatoid arthritis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 RHEUMATOID ARTHRITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 RHEUMATOID ARTHRITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 RHEUMATOID ARTHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 RHEUMATOID ARTHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 RHEUMATOID ARTHRITIS - UNMET NEEDS
10 RHEUMATOID ARTHRITIS - KEY ENDPOINTS OF TREATMENT
11 RHEUMATOID ARTHRITIS - MARKETED PRODUCTS
11.1 List of Rheumatoid Arthritis Marketed Drugs Across the Top 7 Markets
11.1.1 Olumiant (Baricitinib) - Eli Lilly and Company/Incyte Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rinvoq (Upadacitinib) - AbbVie
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Enbrel (Etanercept) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Orencia (Abatacept) - Bristol-Myers Squibb
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Kevzara (Sarilumab) - Regeneron/Sanofi
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 RHEUMATOID ARTHRITIS - PIPELINE DRUGS
12.1 List of Rheumatoid Arthritis Pipeline Drugs Across the Top 7 Markets
12.1.1 ATI-450 - Aclaris Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 MabionCD20 - Mabion SA
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Olokizumab - R-Pharm International, LLC
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 F8IL10 - Philogen
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 HB-adMSCs - Hope Biosciences
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. RHEUMATOID ARTHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. RHEUMATOID ARTHRITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 RHEUMATOID ARTHRITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Rheumatoid Arthritis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Rheumatoid Arthritis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Rheumatoid Arthritis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Rheumatoid Arthritis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Rheumatoid Arthritis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Rheumatoid Arthritis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Rheumatoid Arthritis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Rheumatoid Arthritis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Rheumatoid Arthritis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Rheumatoid Arthritis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Rheumatoid Arthritis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Rheumatoid Arthritis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Rheumatoid Arthritis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Rheumatoid Arthritis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Rheumatoid Arthritis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Rheumatoid Arthritis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Rheumatoid Arthritis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Rheumatoid Arthritis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Rheumatoid Arthritis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Rheumatoid Arthritis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Rheumatoid Arthritis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Rheumatoid Arthritis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Rheumatoid Arthritis - Access and Reimbursement Overview
16 RHEUMATOID ARTHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 RHEUMATOID ARTHRITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 RHEUMATOID ARTHRITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 RHEUMATOID ARTHRITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 RHEUMATOID ARTHRITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 RHEUMATOID ARTHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 RHEUMATOID ARTHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 RHEUMATOID ARTHRITIS - UNMET NEEDS
10 RHEUMATOID ARTHRITIS - KEY ENDPOINTS OF TREATMENT
11 RHEUMATOID ARTHRITIS - MARKETED PRODUCTS
11.1 List of Rheumatoid Arthritis Marketed Drugs Across the Top 7 Markets
11.1.1 Olumiant (Baricitinib) - Eli Lilly and Company/Incyte Corporation
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rinvoq (Upadacitinib) - AbbVie
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Enbrel (Etanercept) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Orencia (Abatacept) - Bristol-Myers Squibb
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Kevzara (Sarilumab) - Regeneron/Sanofi
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 RHEUMATOID ARTHRITIS - PIPELINE DRUGS
12.1 List of Rheumatoid Arthritis Pipeline Drugs Across the Top 7 Markets
12.1.1 ATI-450 - Aclaris Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 MabionCD20 - Mabion SA
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Olokizumab - R-Pharm International, LLC
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 F8IL10 - Philogen
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 HB-adMSCs - Hope Biosciences
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. RHEUMATOID ARTHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. RHEUMATOID ARTHRITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 RHEUMATOID ARTHRITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Rheumatoid Arthritis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Rheumatoid Arthritis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Rheumatoid Arthritis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Rheumatoid Arthritis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Rheumatoid Arthritis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Rheumatoid Arthritis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Rheumatoid Arthritis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Rheumatoid Arthritis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Rheumatoid Arthritis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Rheumatoid Arthritis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Rheumatoid Arthritis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Rheumatoid Arthritis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Rheumatoid Arthritis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Rheumatoid Arthritis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Rheumatoid Arthritis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Rheumatoid Arthritis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Rheumatoid Arthritis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Rheumatoid Arthritis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Rheumatoid Arthritis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Rheumatoid Arthritis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Rheumatoid Arthritis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Rheumatoid Arthritis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Rheumatoid Arthritis - Access and Reimbursement Overview
16 RHEUMATOID ARTHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 RHEUMATOID ARTHRITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 RHEUMATOID ARTHRITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
